Bile Acid Sequestrants Step Therapy Policy
Defines step therapy requirements for bile acid sequestrant products (cholestyramine, colestipol, colesevelam, and branded equivalents) administered under Cigna benefit plans; specifies Step 1 and Step 2 product lists and approval criteria for coverage for Step 2 products.
Annual review entries note 'No criteria changes' for multiple review dates including 06/14/2023, 06/26/2024, and 06/18/2025.
Coverage Summary
Scope: Defines step therapy requirements for bile acid sequestrant products (cholestyramine, colestipol, colesevelam, and branded equivalents) administered under Cigna benefit plans, specifying Step 1 and Step 2 product lists and the requirement that a trial of a Step 1 product is required before a Step 2 product. Coverage stance: these products are covered with step-therapy criteria under Cigna plans; approvals are provided for 1 year. Subject: Bile Acid Sequestrants Step Therapy. Status: CURRENT.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.